RFA FOR BONE METASTASES
PAIN RELIEF WITHOUT SURGERY
Bone metastases cause some of the most severe and debilitating pain in advanced cancer. RFA destroys the tumour and the pain-generating periosteum — providing relief within days rather than weeks, without surgery or additional radiation exposure.
analyticsAt a Glance
- check_circlePain relief in 70–95% of patients — typically noticeable within 24–72 hours of procedure
- check_circleNo surgery, no incision — CT-guided needle access through skin directly to the bone tumour
- check_circleCombined with cementoplasty for weight-bearing bones to prevent fracture
- check_circleCan be repeated for new lesions; no radiation dose accumulation
Why Bone Metastases Cause Such Severe Pain
Understanding bone metastasis pain guides the rationale for why RFA works so effectively for this indication.
“Bone metastasis pain has two components: tumour-related cytokine sensitisation of pain receptors in the periosteum, and mechanical instability from bone destruction. RFA addresses the first; cementoplasty addresses the second. Together they target both pain generators simultaneously.”
The Periosteal Pain Mechanism
The periosteum — the fibrous sheath surrounding bone — is richly innervated with pain fibres. Bone metastases secrete inflammatory cytokines (TNF-α, IL-1, prostaglandins) that sensitise periosteal pain receptors. Even small bone metastases cause disproportionate pain because of this periosteal sensitisation. RFA targets both the tumour cells and the sensitised periosteum — destroying the anatomical substrate of the pain.
Mechanical Pain and Fracture Risk
As tumours destroy bone architecture, structural integrity is compromised. Weight-bearing on weakened bone generates additional mechanical pain — and creates fracture risk. Vertebral collapse, acetabular destruction, and impending fracture of the proximal femur are the most clinically significant. Cementoplasty — filling the ablated cavity with polymethylmethacrylate bone cement — restores load-bearing capacity and eliminates mechanical pain.
Which Bone Metastases Are Suitable for RFA?
Not all bone metastases require or benefit from RFA. Patient and lesion selection is essential for appropriate use.
Painful Lesion Not Controlled by Analgesics
The primary indication. Patients with NRS pain scores ≥4/10 despite adequate analgesic therapy, or those who cannot tolerate the dose of analgesia required for pain control. RFA is a targeted pain intervention — not indicated for asymptomatic bone mets.
Lytic or Mixed Lesion (Not Purely Sclerotic)
Lytic lesions (bone destruction with soft tissue component) respond best to RFA — the electrode can be placed within the soft tissue component and ablation zone achieves tumour necrosis. Pure sclerotic bone metastases are harder to ablate effectively due to the dense bone impeding electrode penetration and heat spread.
Single or Oligofocal Painful Lesion
RFA is most practical for 1–3 discrete painful lesions. Diffuse multifocal bone pain from widespread metastatic disease is better managed with systemic treatments (bisphosphonates, denosumab, systemic radiopharmaceuticals like radium-223). RFA addresses the dominant pain lesion while systemic treatment continues.
Weight-Bearing Bones: Combined RFA + Cementoplasty
Vertebral bodies, sacrum, acetabulum, proximal femur — weight-bearing bones at risk of fracture. For these locations, RFA is followed immediately in the same session by cementoplasty (cement injection into the ablated cavity). This combination addresses both the pain and the structural deficit in a single procedure.
Pain Relief Outcomes: Published Data
Published pain response rates from major bone RFA series using validated pain scoring tools.
Pain Relief After Bone RFA — Key Outcomes
Pain response defined as ≥2-point reduction in NRS (0–10) at 3 months. OPuS Trial (Callstrom et al., JCO 2006) was the pivotal prospective multicentre trial for bone RFA.
- Pain Response (≥2-point NRS reduction) at 1 Month70–85%
- Pain Response at 3 Months75–95%
- Complete Pain Relief at 3 Months25–45%
- Opioid Dose Reduction at 3 Months45–65%
RFA + Cementoplasty Procedure for Weight-Bearing Bone Metastases
The combined RFA + cementoplasty procedure for vertebral and other weight-bearing bone metastases — performed in a single session under general or spinal anaesthesia.
- 1
Step 1: Pre-Procedure Planning
CT review confirming lesion size, bone cortex integrity, proximity to spinal cord or other neural structures. Bone scan or SPECT-CT identifying dominant painful lesion. Coagulation screen. Any neurological symptoms from vertebral lesions fully documented (to identify spinal cord compression which may require different urgent management).
- 2
Step 2: CT-Guided Electrode Placement
Under CT or fluoroscopy guidance, a bone needle (trocar) is advanced through the skin and cortical bone into the tumour. For vertebral lesions, a transpedicular approach (through the pedicle of the vertebra) provides safe access while protecting the spinal canal. For acetabular or iliac lesions, a direct posterior percutaneous approach is typical.
- 3
Step 3: RFA — Tumour and Periosteum Ablation
RFA electrode delivered through the bone trocar. Energy delivered to achieve 60–100°C throughout the tumour mass, extending to the periosteum. Ablation duration 6–15 minutes depending on tumour size and electrode system. Multiple electrode positions may be needed for larger lesions.
- 4
Step 4: Cementoplasty (Immediately After RFA, Same Session)
The bone needle used for RFA access is used to inject polymethylmethacrylate (PMMA) bone cement under fluoroscopic or CT guidance. Cement fills the ablated cavity, restores bone strength, and provides additional thermal and mechanical pain relief. Cement hardens within 20–30 minutes. The trocar is removed and the skin entry closed with a small adhesive dressing.
- 5
Step 5: Recovery
Most patients mobilised within 4–6 hours of procedure. Overnight stay typically. Bisphosphonate or denosumab bone protection treatment continued. Pain relief often noticed within 24 hours; typically maximal by 72 hours as periosteal inflammation settles. Weight-bearing on cement-stabilised bones usually resumes within 24 hours.
RFA vs Radiation for Bone Metastasis Pain
Both RFA and palliative external beam radiation (EBRT) are effective for bone metastasis pain relief. Understanding their differences helps patients and clinicians choose the appropriate approach.
RFA Advantages
- Faster Pain Relief24–72 hours vs 2–4 weeks for radiation. Critically important for patients with severe uncontrolled pain.
- No Radiation Dose AccumulationCan be repeated for new lesions without concern about prior radiation to adjacent critical structures.
- Structural ReinforcementCementoplasty in the same session addresses fracture risk — radiation alone does not provide mechanical support.
- Local Tissue DestructionActually destroys tumour cells at the site — not just nerve desensitisation.
Radiation Advantages
- Non-Invasive — No NeedleExternal beam radiation requires no needle access — suitable when anatomical location makes percutaneous access difficult or risky.
- Treats Entire Bone RegionRadiation treats the full irradiated field — useful for diffuse disease within a bone region.
- More Widely AvailableRadiotherapy is available at virtually all cancer centres; bone RFA requires interventional radiology expertise.
- Equally Effective for Uncomplicated CasesFor non-weight-bearing bone mets without fracture risk, radiation and RFA achieve similar long-term pain control.
Explore the RFA Knowledge Base
Related interventional oncology topics.
Frequently Asked Questions
Common questions about RFA for bone metastases.
About the Treatment
I have multiple painful bone metastases — can RFA treat all of them?
RFA is most practical for treating the one or two dominant painful lesions. For patients with diffuse bone metastasis pain affecting multiple sites, systemic approaches — bisphosphonates, denosumab, radium-223 (for prostate cancer), lutetium-177-PSMA (for prostate), or other systemic treatments — address the broader disease. RFA can treat the worst lesion or lesion with fracture risk while systemic treatment continues. CancerFax can assess which lesion is causing the dominant pain and most appropriate for RFA targeting.
Is bone RFA safe near the spine?
Vertebral RFA is performed routinely at experienced centres with appropriate attention to spinal canal safety. The ablation zone must be kept away from the spinal cord and nerve roots — the critical safety margin. At experienced interventional radiology centres, this is achieved through careful electrode positioning under CT guidance. A temperature monitoring electrode placed at the spinal canal margin can monitor heat propagation during ablation. Vertebral RFA near the spinal cord is higher risk than peripheral bone lesions and requires specialist expertise.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Painful Bone Metastasis Not Controlled by Analgesics?
Upload your CT/MRI/bone scan and pain history. Our interventional oncology team will assess whether RFA — with or without cementoplasty — is appropriate for your dominant bone metastasis.
For informational purposes only. Bone metastasis pain management requires evaluation by qualified oncology and interventional radiology specialists.